Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cabergoline Clear all
Completed Phase 2 Interventional Results available

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

NCT06029673
View directory record Official record
Conditions
Lactation Suppressed
Interventions
Cabergoline 1 MG, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 18, 2026, 2:40 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

NCT07492160
View directory record Official record
Conditions
Pregnancy, Abortion
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
Jefferson Drapkin
Other
Eligibility
18 Years and older · Female only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

NCT00605683
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
View directory record Official record
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Interventions
Pasireotide, Cabergoline, Pasireotide LAR
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Cabergoline Before or After Oocyte Collection for Follicular Resolution

NCT04096027
View directory record Official record
Conditions
Infertility, Female
Interventions
Cabergoline Pill
Drug
Lead sponsor
Fertility Center of Las Vegas
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

NCT02685709
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide capsules
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional

A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

NCT00033111
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Torrance, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 18, 2026, 2:40 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

NCT01915303
View directory record Official record
Conditions
Cushings Disease
Interventions
Pasireotide with or without cabergoline
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Cabergoline on Weight and Glucose Tolerance

NCT01395602
View directory record Official record
Conditions
Body Weight, Impaired Glucose Tolerance in Obese
Interventions
Cabergoline, placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional

Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

NCT03928288
View directory record Official record
Conditions
Endometriosis
Interventions
Cabergoline 0.5 MG, Placebo - Cap
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

NCT00242008
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Early Phase 1 Interventional Results available

Cabergoline in Metastatic Breast Cancer

NCT01730729
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
cabergoline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

NCT06123026
View directory record Official record
Conditions
Lactation Suppressed, Second Trimester Abortion
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence

NCT01651364
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Substance Abuse
Interventions
Placebo, Cabergoline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

NCT02542410
View directory record Official record
Conditions
Endometriosis
Interventions
Cabergoline, Norethindrone acetate
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 18, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

NCT04701333
View directory record Official record
Conditions
Lactation Suppressed
Interventions
Cabergoline 1 MG, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 18, 2026, 2:40 PM EDT